CIRCULOGENE

CIRCULOGENE provides the Best-in-Class liquid biopsy including the ONLY plasma PD-L1.
Patients deserve the BEST.

[CIRCULOGENE @circulogene_bio]

Liquid Biopsy is Supported @IASLC Recommendation: Liquid biopsy is acceptable as the initial approach (“plasma first”) at the time of diagnosis and for monitoring the efficacy of targeted therapies. CIRCULOGENE is a Best-in-Class liquid biopsy with the ONLY plasma PD-L1.

[CIRCULOGENE @circulogene_bio]

CIRCULOGENE is the Best-in-Class liquid biopsy offering the ONLY plasma PD-L1. Know which patients will benefit from immunotherapy. Patients deserve the BEST!!!

[IASLC @IASLC]

Fact: #Lungcancer is not created equal. It is essential that all patients with advanced non-squamous #NSCLC undergo genomic profiling and PD-L1 testing, to identify which treatment may be best for their lung cancer. #LCSM #LCAM22

[CIRCULOGENE @circulogene_bio]

In NSCLC patients, it is critical to understand if a patient will respond to chemotherapy or immunotherapy. CIRCULOGENE can provide the FASTEST PD-L1 via liquid biopsy within 7 days! CIRCLOGENE is Best-in-Class and Patients deserve the BEST!!!

[IASLC @IASLC]

Fact: A treatment strategy based on biomarker testing is the most effective way of treating #lungcancer. #LCSM #LCAM22

[CIRCULOGENE @circulogene_bio]

Personalized Medicine results in better outcomes and survival rates. Understanding the molecular profile assists targeted therapies for patients' cancers. CIRCULOGENE is Best-in-Class liquid biopsy with the ONLY plasma PD-L1. Patients deserve the BEST!!!

[CIRCULOGENE @circulogene_bio]

.@Hopkinskimmel research reduced the use of chemo in stage II colon cancer and did not compromise survival. https://t.co/Q0pCgHQ4u3

[CIRCULOGENE @circulogene_bio]

Chemotherapy or Immunotherapy? Determining the best treatment for the patient is essential for outcomes and survivals. Knowing the molecular profile of the cancer is key. CIRCULOGENE with the ONLY plasma PD-L1 should be performed on ALL lung cancer patients.

[CIRCULOGENE @circulogene_bio]

Treating pancreatic cancer has better outcomes and survival rates when the treatment matches the molecular profile. CIRCULOGENE is the Best-in-Class liquid profile at time of diagnosis and post treatment to determine patient response. Patients deserve the BEST.

[CIRCULOGENE @circulogene_bio]

Each patient’s cancer is unique, understanding the the cancers aids to personalize the patient’s treatment plan at the time of diagnosis. ALL lung cancer patients should have a molecular profile to determine the best course of treatment. Patients deserve the BEST!!!

[CIRCULOGENE @circulogene_bio]

Pancreatic cancer patients should have both molecular profiling and genetic testing. All patients should have a molecular profile before treatment for best outcomes. CIRCULOGENE offers the Best-in-Class liquid biopsy. Patients deserve the BEST
https://t.co/3oZKxH0Jma via @pancan

[CIRCULOGENE @circulogene_bio]

November is Lung Cancer Awareness Month. @circulogene_bio supports providers and patient advocacy groups with the Best-of-Class liquid biopsy with the ONLY plasma PD-L1. Getting the right treatment faster!!! Patients deserve the Best! https://t.co/hGEa8EV0ko

[CIRCULOGENE @circulogene_bio]

Genomic Testing and ctDNA Add to Personalized Treatment Approach in Metastatic CRC. CIRCULOGENE Best-in-Class liquid biopsy offers the most sensitive MSI and ONLY PD-L1 to personalize treatment for cancer patients. Patients deserve the BEST https://t.co/EYgOfuk3bO via @onclive

[CIRCULOGENE @circulogene_bio]

@NCCN recommends MSI and Germline testing for CRC patients. @circulogene_bio offers a Best-in-Class liquid biopsy with the most sensitive MSI and a complete NCCN marker germline panel. Patients deserve the BEST!
https://t.co/20GUM32jxO

[CIRCULOGENE @circulogene_bio]

Dr. Paul Walker presents a Molecular Tumor Board - metastatic melanoma with a normal LDH. Remarkable markers include CDKN2A and PD-L1. CIRCULOGENE is the Best-in-Class liquid biopsy with the ONLY plasma PD-L1.
https://t.co/NMfvUatwSd

[CIRCULOGENE @circulogene_bio]

Predictive biomarker of response to therapy in patients with microsatellite stable metastatic colorectal cancer. CIRCULOGENE is a Best-in-Class liquid biopsy at time of diagnosis (baseline) and for patient response to therapy. https://t.co/G96Ue90H2i via @medical_xpress

[CIRCULOGENE @circulogene_bio]

Knowing the PD-L1 result is key to determining chemotherapy or immunotherapy for NSCLC patients. CIRCULOGENE is ONLY plasma PD-L1 making it the Best-in-Class liquid biopsy. Patients deserve the BEST!!! @IASLC @circulogene_bio

[Liquid Biopsy @biopsy_liquid]

The presence of circulating tumor DNA (ctDNA) after surgery predicts very poor recurrence-free survival, whereas its absence predicts a low risk of recurrence.
📚 Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer
.
#liquidbiopsy #coloncancer #tumor

[CIRCULOGENE @circulogene_bio]

Dr Paul Walker conducts a Virtual Tumor Board in a lung cancer patient with a CIRCULOGENE SMARCA4 marker. This discussion shares the patient background as well as studies indicating the probable treatment of the NSCLC patient. Patients deserve the BEST!!!
https://t.co/RFudZNWAB1

[CIRCULOGENE @circulogene_bio]

Patients with MSI-H colorectal cancer who received immunotherapy had fewer treatment-related adverse events. @ASCOPost CIRCULOGENE liquid biopsy offers the most sensitive MSI detection - making it Best-In-Class. Patients deserve the BEST!!!
https://t.co/jrApPH2n6D

[CIRCULOGENE @circulogene_bio]

CIRCULOGENE is offering a virtual tumor board with Dr. Paul Walker reviewing patient results and providing supporting articles/studies with each determination. This first in a series is MSI-H in a colorectal cancer patient. Patients deserve the BEST!!!
https://t.co/3WRbrZg4fb

[CIRCULOGENE @circulogene_bio]

Exploring Molecular Testing in CRC Treatment - Liquid biopsy is clinically beneficial at time of diagnosis and post treatment/surgery for patient response. CIRCULOGENE is the Best-in-Class liquid biopsy. Patients deserve the BEST! https://t.co/ddX8vkP2pS via @AJMC_Journal